Peter G Hendrickson
Overview
Explore the profile of Peter G Hendrickson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
483
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burner D, Hendrickson P, Cardona D, Blazer 3rd D, Mullins J, Kirsch D
Adv Radiat Oncol
. 2025 Jan;
10(2):101689.
PMID: 39810995
Purpose: Optimal treatment of retroperitoneal sarcoma (RPS) remains undefined. Here, we report the feasibility of using high-dose boost radiation (3-4 Gy) to the central part of the tumor in patients...
2.
Leng J, Su C, Carpenter D, Floyd W, Vaios E, Shenker R, et al.
J Radiosurg SBRT
. 2024 Aug;
9(2):91-99.
PMID: 39087065
Purpose: To investigate whether TP53 variants may be correlated with overall survival and local control following stereotactic radiosurgery (SRS) for brain metastases (BMs) from non-small cell lung cancer (NSCLC). Methods:...
3.
Binkley M, Flerlage J, Savage K, Akhtar S, Steiner R, Zhang X, et al.
J Clin Oncol
. 2024 Mar;
42(19):2271-2280.
PMID: 38531001
Purpose: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and immunoarchitectural patterns (IAPs) for...
4.
Hendrickson P, Oristian K, Browne M, Luo L, Ma Y, Cardona D, et al.
Oncogene
. 2024 Feb;
43(16):1223-1230.
PMID: 38413794
CIC::DUX4 sarcoma (CDS) is a rare but highly aggressive undifferentiated small round cell sarcoma driven by a fusion between the tumor suppressor Capicua (CIC) and DUX4. Currently, there are no...
5.
Vaios E, Shenker R, Hendrickson P, Wan Z, Niedzwiecki D, Winter S, et al.
Int J Radiat Oncol Biol Phys
. 2023 Dec;
118(5):1507-1518.
PMID: 38097090
Purpose: The intracranial benefit of offering dual immune-checkpoint inhibition (D-ICPI) with ipilimumab and nivolumab to patients with melanoma or non-small cell lung cancer (NSCLC) receiving stereotactic radiosurgery (SRS) for brain...
6.
Hendrickson P, Oristian K, Browne M, Luo L, Ma Y, Cardona D, et al.
Res Sq
. 2023 Nov;
PMID: 37961185
CIC-DUX4 sarcoma (CDS) is a rare but highly aggressive undifferentiated small round cell sarcoma driven by a fusion between the tumor suppressor Capicua (CIC) and DUX4. Currently, there are no...
7.
Hendrickson P, Oristian K, Browne M, Lou L, Ma Y, Cardona D, et al.
bioRxiv
. 2023 Oct;
PMID: 37808628
CIC-DUX4 sarcoma (CDS) is a rare but highly aggressive undifferentiated small round cell sarcoma driven by a fusion between the tumor suppressor Capicua (CIC) and DUX4. Currently, there are no...
8.
Tu K, Stewart C, Hendrickson P, Regal J, Kim S, Ashley D, et al.
Oncogene
. 2023 Sep;
42(44):3274-3286.
PMID: 37741952
Pooled genetic screens represent a powerful approach to identify vulnerabilities in cancer. Here we used pooled CRISPR/Cas9-based approaches to identify vulnerabilities associated with telomerase reverse transcriptase (TERT) promoter mutations (TPMs)...
9.
Grow E, Weaver B, Smith C, Guo J, Stein P, Shadle S, et al.
Nat Genet
. 2021 Jul;
53(8):1207-1220.
PMID: 34267371
In mammalian embryos, proper zygotic genome activation (ZGA) underlies totipotent development. Double homeobox (DUX)-family factors participate in ZGA, and mouse Dux is required for forming cultured two-cell (2C)-like cells. Remarkably,...
10.
Hendrickson P, Luo Y, Kohlmann W, Schiffman J, Maese L, Bishop A, et al.
Cancer Med
. 2020 Sep;
9(21):7954-7963.
PMID: 32931654
Background: Li-Fraumeni Syndrome (LFS) is a rare cancer-predisposing condition caused by germline mutations in TP53. Conventional wisdom and prior work has implied an increased risk of secondary malignancy in LFS...